Return to content in this issue

 

Real-life Experience of Subcutaneous Plasma Derived C1-Inhibitor as Long-term Prophylaxis in HAE-C1INH

Entrala A1,2,3, Loli-Ausejo D4, Pérez T5, Losantos I6, Cabañas R1,2,3,7,8, Caballero T1,2,3,7

1Department of Allergy, Hospital Universitario La Paz, Madrid, Spain
2Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
3CSUR de Angioedema Hereditario, Hospital Universitario La Paz, Madrid, Spain
4Department of Allergy, Hospital Clinic de Barcelona, Universitat de Barcelona, Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
5Department of Pharmacy, Hospital Universitario La Paz, Madrid, Spain
6Department of Biostatistics, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
7Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, Spain
8PIELenRed Consortium

J Investig Allergol Clin Immunol 2024; Vol 34(4) : 261-263
doi: 10.18176/jiaci.0977

Key words: Hereditary angioedema due to C1-inhibitor deficiency, AEQoL, HAE-QoL, Subcutaneous plasmaderived C1-INH